Predictive Framework for Optimizing Plerixafor Use in Pediatric Stem Cell Mobilization
Overview
A predictive linear model was developed to correlate peripheral blood CD34+ cell counts prior to apheresis with the yield of collected CD34+ cells in children undergoing autologous stem cell transplantation. The model demonstrated a strong correlation (r = 0.84) and can guide plerixafor administration to improve mobilization outcomes in pediatric patients.
Background
Autologous hematopoietic stem cell transplantation is a critical treatment for various pediatric cancers including neuroblastoma, lymphomas, and solid tumors. Successful mobilization and collection of peripheral blood CD34+ stem cells are essential for engraftment and recovery. While granulocyte colony-stimulating factor (G-CSF) is commonly used for mobilization, failure rates range from 8–27%. Plerixafor, a CXCR4 antagonist, has shown efficacy in adults and is approved for use in children to enhance mobilization, but limited pediatric data exist. The MOZAIC trial evaluated plerixafor plus G-CSF versus G-CSF alone in children, demonstrating improved mobilization with plerixafor.
Data Highlights
Parameter
Value
Correlation coefficient (r)
0.84
Number of pediatric patients (Stage-2 MOZAIC)
45
Patients meeting primary endpoint in plerixafor arm
24/30 (80%)
Patients meeting primary endpoint in G-CSF arm
4/14 (28.6%)
Percentage with single apheresis day
84% (38/45)
Key Findings
A strong linear relationship exists between peripheral blood CD34+ counts before apheresis and collected CD34+ cell yield (r = 0.84).
Plerixafor combined with G-CSF significantly increased the proportion of pediatric patients achieving successful mobilization compared to G-CSF alone (80% vs 28.6%, p = 0.0019).
The predictive model used an untransformed linear approach, which outperformed log-transformed models in accuracy.
Most patients (over 84%) required only a single day of apheresis for stem cell collection.
Error structure analysis indicated that residual variability was not homogenous, prompting exploration of proportional error models.
Clinical Implications
This predictive framework allows clinicians to estimate stem cell collection yield based on peripheral blood CD34+ counts, facilitating timely and optimized use of plerixafor in children at risk of mobilization failure. Early identification of poor mobilizers can reduce apheresis days and improve resource utilization. Incorporating this model into clinical practice may enhance autologous transplant outcomes in pediatric oncology.
Conclusion
The study establishes a robust predictive model linking peripheral blood CD34+ counts to stem cell harvest in pediatric patients, supporting optimized plerixafor administration. This approach can improve mobilization success and streamline autologous transplantation protocols in children.
References
MOZAIC Trial (NCT01288573) -- Plerixafor plus G-CSF in Pediatric Stem Cell Mobilization
Sanofi -- Plerixafor (Mozobil®) Product Information
Clinical Studies in Adults -- Plerixafor Efficacy in Multiple Myeloma and NHL
